Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1530 entries
Sorted by: Best Match Show Resources per page
Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.

Journal of clinical movement disorders

Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE.
PMID: 27231577
J Clin Mov Disord. 2016 May 26;3:8. doi: 10.1186/s40734-016-0036-9. eCollection 2016.

BACKGROUND: The modulation of levodopa transport across the blood brain barrier by large neutral amino acids is well documented. Protein limitation and protein redistribution diets may improve motor fluctuations in patients with Parkinson's disease but the pharmacokinetics and pharmacodynamics...

Cite
Virmani T, Tazan S, Mazzoni P, et al. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease. J Clin Mov Disord. 2016;3:8doi: 10.1186/s40734-016-0036-9.
Virmani, T., Tazan, S., Mazzoni, P., Ford, B., & Greene, P. E. (2016). Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease. Journal of clinical movement disorders, 38. https://doi.org/10.1186/s40734-016-0036-9
Virmani, Tuhin, et al. "Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease." Journal of clinical movement disorders vol. 3 (2016): 8. doi: https://doi.org/10.1186/s40734-016-0036-9
Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease. J Clin Mov Disord. 2016 May 26;3:8. doi: 10.1186/s40734-016-0036-9. eCollection 2016. PMID: 27231577; PMCID: PMC4881294.
Copy Download .nbib Format: NLM
Levodopa-induced facial dystonia in a case of progressive supranuclear palsy.

Journal of movement disorders

Chung EJ, Kim SJ.
PMID: 24868411
J Mov Disord. 2012 May;5(1):28-32. doi: 10.14802/jmd.12008. Epub 2012 May 30.

Progressive supranuclear palsy (PSP) is frequently misdiagnosed as other Parkinsonism because of clinical heterogeneity of PSP. We present here a case of a 67-year-old male patient with frontotemporal dementia-like cognitive impairment including language difficulties and abnormal behaviors. He showed...

Cite
Chung EJ, Kim SJ. Levodopa-induced facial dystonia in a case of progressive supranuclear palsy. J Mov Disord. 2012;5(1):28-32doi: 10.14802/jmd.12008.
Chung, E. J., & Kim, S. J. (2012). Levodopa-induced facial dystonia in a case of progressive supranuclear palsy. Journal of movement disorders, 5(1), 28-32. https://doi.org/10.14802/jmd.12008
Chung, Eun Joo, and Kim, Sang Jin. "Levodopa-induced facial dystonia in a case of progressive supranuclear palsy." Journal of movement disorders vol. 5,1 (2012): 28-32. doi: https://doi.org/10.14802/jmd.12008
Chung EJ, Kim SJ. Levodopa-induced facial dystonia in a case of progressive supranuclear palsy. J Mov Disord. 2012 May;5(1):28-32. doi: 10.14802/jmd.12008. Epub 2012 May 30. PMID: 24868411; PMCID: PMC4027676.
Copy Download .nbib Format: NLM
Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up.

Translational neurodegeneration

Li D, Cao C, Zhang J, Zhan S, Chen S, Sun B.
PMID: 23706134
Transl Neurodegener. 2013 May 24;2(1):11. doi: 10.1186/2047-9158-2-11.

OBJECTIVE: The short-term benefits of bilateral stimulation of the subthalamic nucleus (STN) in patients with advanced Parkinson's disease (PD) are well documented, but long-term benefits are still uncertain. The aim of this study is to evaluate the outcome of...

Cite
Li D, Cao C, Zhang J, et al. Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up. Transl Neurodegener. 2013;2(1):11doi: 10.1186/2047-9158-2-11.
Li, D., Cao, C., Zhang, J., Zhan, S., Chen, S., & Sun, B. (2013). Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up. Translational neurodegeneration, 2(1), 11. https://doi.org/10.1186/2047-9158-2-11
Li, Dianyou, et al. "Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up." Translational neurodegeneration vol. 2,1 (2013): 11. doi: https://doi.org/10.1186/2047-9158-2-11
Li D, Cao C, Zhang J, Zhan S, Chen S, Sun B. Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up. Transl Neurodegener. 2013 May 24;2(1):11. doi: 10.1186/2047-9158-2-11. PMID: 23706134; PMCID: PMC3667054.
Copy Download .nbib Format: NLM
Anticholinergic agents can induce oromandibular dyskinesia.

Journal of movement disorders

Shin HY, Yoon WT, Lee WY.
PMID: 24868360
J Mov Disord. 2009 Oct;2(2):69-71. doi: 10.14802/jmd.09018. Epub 2009 Oct 30.

BACKGROUND AND PURPOSE: Oromandibular dyskinesia (OMD) can occur spontaneously or they can be induced by the conventional dopamine receptor antagonists. Anticholinergic medications have rarely been reported to cause OMD in parkinsonian or non-parkinsonian patients.METHODS: We analyzed the clinical features...

Cite
Shin HY, Yoon WT, Lee WY. Anticholinergic agents can induce oromandibular dyskinesia. J Mov Disord. 2009;2(2):69-71doi: 10.14802/jmd.09018.
Shin, H. Y., Yoon, W. T., & Lee, W. Y. (2009). Anticholinergic agents can induce oromandibular dyskinesia. Journal of movement disorders, 2(2), 69-71. https://doi.org/10.14802/jmd.09018
Shin, Hee-Young, et al. "Anticholinergic agents can induce oromandibular dyskinesia." Journal of movement disorders vol. 2,2 (2009): 69-71. doi: https://doi.org/10.14802/jmd.09018
Shin HY, Yoon WT, Lee WY. Anticholinergic agents can induce oromandibular dyskinesia. J Mov Disord. 2009 Oct;2(2):69-71. doi: 10.14802/jmd.09018. Epub 2009 Oct 30. PMID: 24868360; PMCID: PMC4027716.
Copy Download .nbib Format: NLM
Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study.

American health & drug benefits

Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T.
PMID: 24991332
Am Health Drug Benefits. 2012 Sep;5(6):347-58.

BACKGROUND: No curative therapy is available for Parkinson's disease; therefore, one of the main goals of treatment is to control motor symptoms, often via the use of levodopa (also known as L-dopa). However, prolonged levodopa treatment in Parkinson's disease...

Cite
Lennert B, Bibeau W, Farrelly E, et al. Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study. Am Health Drug Benefits. 2012;5(6):347-58
Lennert, B., Bibeau, W., Farrelly, E., Sacco, P., & Schoor, T. (2012). Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study. American health & drug benefits, 5(6), 347-58.
Lennert, Barb, et al. "Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study." American health & drug benefits vol. 5,6 (2012): 347-58.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study. Am Health Drug Benefits. 2012 Sep;5(6):347-58. PMID: 24991332; PMCID: PMC4031696.
Copy Download .nbib Format: NLM
Selegiline-citalopram combination in patients with Parkinson's disease and major depression.

International journal of psychiatry in clinical practice

Rihmer Maria Satori Peter Pestality Z.
PMID: 24921447
Int J Psychiatry Clin Pract. 2000;4(2):123-5. doi: 10.1080/13651500050518280.

INTRODUCTION: We evaluated the efficacy and safety of the selegiline citalopram combination in the treatment of major depression in patients with Parkinson's disease.METHOD: Eight consecutive depressed outpatients who had received previously selegiline monotherapy or (one patient) selegiline-levodopa combination (the...

Cite
Rihmer Maria Satori Peter Pestality Z. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract. 2000;4(2):123-5doi: 10.1080/13651500050518280.
Rihmer Maria Satori Peter Pestality, Z. (2000). Selegiline-citalopram combination in patients with Parkinson's disease and major depression. International journal of psychiatry in clinical practice, 4(2), 123-5. https://doi.org/10.1080/13651500050518280
Rihmer Maria Satori Peter Pestality, Z. "Selegiline-citalopram combination in patients with Parkinson's disease and major depression." International journal of psychiatry in clinical practice vol. 4,2 (2000): 123-5. doi: https://doi.org/10.1080/13651500050518280
Rihmer Maria Satori Peter Pestality Z. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract. 2000;4(2):123-5. doi: 10.1080/13651500050518280. PMID: 24921447.
Copy Download .nbib Format: NLM
Comprehensive treatment of dementia with Lewy bodies.

Alzheimer's research & therapy

Boot BP.
PMID: 26029267
Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015.

Dementia with Lewy bodies is an under-recognized disease; it is responsible for up to 20 % of all dementia cases. Accurate diagnosis is essential because the management of dementia with Lewy bodies is more complex than many neurodegenerative diseases....

Cite
Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015;7(1):45doi: 10.1186/s13195-015-0128-z.
Boot, B. P. (2015). Comprehensive treatment of dementia with Lewy bodies. Alzheimer's research & therapy, 7(1), 45. https://doi.org/10.1186/s13195-015-0128-z
Boot, Brendon P. "Comprehensive treatment of dementia with Lewy bodies." Alzheimer's research & therapy vol. 7,1 (2015): 45. doi: https://doi.org/10.1186/s13195-015-0128-z
Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015. PMID: 26029267; PMCID: PMC4448151.
Copy Download .nbib Format: NLM
Dynamic changes of five neurotransmitters and their related enzymes in various rat tissues following β-asarone and levodopa co-administration.

Experimental and therapeutic medicine

Huang L, Deng M, Fang Y, Li L.
PMID: 26622527
Exp Ther Med. 2015 Oct;10(4):1566-1572. doi: 10.3892/etm.2015.2704. Epub 2015 Aug 24.

The aim of the present study was to investigate the dynamic changes of five neurotransmitters and their associated enzymes in the rat plasma and brain tissues following the co-administration of β-asarone and levodopa (L-dopa). The rats were divided into...

Cite
Huang L, Deng M, Fang Y, et al. Dynamic changes of five neurotransmitters and their related enzymes in various rat tissues following β-asarone and levodopa co-administration. Exp Ther Med. 2015;10(4):1566-1572doi: 10.3892/etm.2015.2704.
Huang, L., Deng, M., Fang, Y., & Li, L. (2015). Dynamic changes of five neurotransmitters and their related enzymes in various rat tissues following β-asarone and levodopa co-administration. Experimental and therapeutic medicine, 10(4), 1566-1572. https://doi.org/10.3892/etm.2015.2704
Huang, Liping, et al. "Dynamic changes of five neurotransmitters and their related enzymes in various rat tissues following β-asarone and levodopa co-administration." Experimental and therapeutic medicine vol. 10,4 (2015): 1566-1572. doi: https://doi.org/10.3892/etm.2015.2704
Huang L, Deng M, Fang Y, Li L. Dynamic changes of five neurotransmitters and their related enzymes in various rat tissues following β-asarone and levodopa co-administration. Exp Ther Med. 2015 Oct;10(4):1566-1572. doi: 10.3892/etm.2015.2704. Epub 2015 Aug 24. PMID: 26622527; PMCID: PMC4578043.
Copy Download .nbib Format: NLM
Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Neuropsychiatric disease and treatment

Cui G, Yang X, Wang X, Zhang Z, Yue X, Shi H, Shen X.
PMID: 24379672
Neuropsychiatr Dis Treat. 2014;10:39-46. doi: 10.2147/NDT.S54782. Epub 2013 Dec 18.

BACKGROUND: Chronic administration of levodopa in Parkinson's disease leads to debilitating involuntary movements, termed levodopa-induced dyskinesia (LID). The pathogenesis of LID is poorly understood. Previous research has shown that histamine H2 receptors are highly expressed in the input (striatum)...

Cite
Cui G, Yang X, Wang X, et al. Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat. 2013;10:39-46doi: 10.2147/NDT.S54782.
Cui, G., Yang, X., Wang, X., Zhang, Z., Yue, X., Shi, H., & Shen, X. (2014). Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatric disease and treatment, 1039-46. https://doi.org/10.2147/NDT.S54782
Cui, Guiyun, et al. "Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson's disease." Neuropsychiatric disease and treatment vol. 10 (2014): 39-46. doi: https://doi.org/10.2147/NDT.S54782
Cui G, Yang X, Wang X, Zhang Z, Yue X, Shi H, Shen X. Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat. 2014;10:39-46. doi: 10.2147/NDT.S54782. Epub 2013 Dec 18. PMID: 24379672; PMCID: PMC3872142.
Copy Download .nbib Format: NLM
Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo.

Journal of neurochemistry

Harun R, Hare KM, Brough EM, Munoz MJ, Grassi CM, Torres GE, Grace AA, Wagner AK.
PMID: 26611352
J Neurochem. 2016 Mar;136(6):1270-1283. doi: 10.1111/jnc.13444. Epub 2016 Jan 13.

Parkinson's disease (PD) is a debilitating condition that is caused by a relatively specific degeneration of dopaminergic (DAergic) neurons of the substantia nigra pars compacta. L-DOPA was introduced as a viable treatment option for PD over 40 years ago...

Cite
Harun R, Hare KM, Brough EM, et al. Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo. J Neurochem. 2016;136(6):1270-1283doi: 10.1111/jnc.13444.
Harun, R., Hare, K. M., Brough, E. M., Munoz, M. J., Grassi, C. M., Torres, G. E., Grace, A. A., & Wagner, A. K. (2016). Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo. Journal of neurochemistry, 136(6), 1270-1283. https://doi.org/10.1111/jnc.13444
Harun, Rashed, et al. "Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo." Journal of neurochemistry vol. 136,6 (2016): 1270-1283. doi: https://doi.org/10.1111/jnc.13444
Harun R, Hare KM, Brough EM, Munoz MJ, Grassi CM, Torres GE, Grace AA, Wagner AK. Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo. J Neurochem. 2016 Mar;136(6):1270-1283. doi: 10.1111/jnc.13444. Epub 2016 Jan 13. PMID: 26611352; PMCID: PMC4884169.
Copy Download .nbib Format: NLM
Levodopa-responsive depression associated with corticobasal degeneration: a case report.

Neuropsychiatric disease and treatment

Tarakita N, Nishijima H, Yasui-Furukori N.
PMID: 28458551
Neuropsychiatr Dis Treat. 2017 Apr 18;13:1107-1110. doi: 10.2147/NDT.S136706. eCollection 2017.

A 60-year-old female was treated for depression with the antidepressant paroxetine for 13 years. The patient had experienced clumsiness and mild rigidity in the left hand, and had agraphia and mild subjective memory complaints for 3 years prior to...

Cite
Tarakita N, Nishijima H, Yasui-Furukori N. Levodopa-responsive depression associated with corticobasal degeneration: a case report. Neuropsychiatr Dis Treat. 2017;13:1107-1110doi: 10.2147/NDT.S136706.
Tarakita, N., Nishijima, H., & Yasui-Furukori, N. (2017). Levodopa-responsive depression associated with corticobasal degeneration: a case report. Neuropsychiatric disease and treatment, 131107-1110. https://doi.org/10.2147/NDT.S136706
Tarakita, Natsumi, et al. "Levodopa-responsive depression associated with corticobasal degeneration: a case report." Neuropsychiatric disease and treatment vol. 13 (2017): 1107-1110. doi: https://doi.org/10.2147/NDT.S136706
Tarakita N, Nishijima H, Yasui-Furukori N. Levodopa-responsive depression associated with corticobasal degeneration: a case report. Neuropsychiatr Dis Treat. 2017 Apr 18;13:1107-1110. doi: 10.2147/NDT.S136706. eCollection 2017. PMID: 28458551; PMCID: PMC5402995.
Copy Download .nbib Format: NLM
DYNAMIC PREDICTION FOR MULTIPLE REPEATED MEASURES AND EVENT TIME DATA: AN APPLICATION TO PARKINSON'S DISEASE.

The annals of applied statistics

Wang J, Luo S, Li L.
PMID: 29081873
Ann Appl Stat. 2017 Sep;11(3):1787-1809. doi: 10.1214/17-AOAS1059. Epub 2017 Oct 05.

In many clinical trials studying neurodegenerative diseases such as Parkinson's disease (PD), multiple longitudinal outcomes are collected to fully explore the multidimensional impairment caused by this disease. If the outcomes deteriorate rapidly, patients may reach a level of functional...

Cite
Wang J, Luo S, Li L. DYNAMIC PREDICTION FOR MULTIPLE REPEATED MEASURES AND EVENT TIME DATA: AN APPLICATION TO PARKINSON'S DISEASE. Ann Appl Stat. 2017;11(3):1787-1809doi: 10.1214/17-AOAS1059.
Wang, J., Luo, S., & Li, L. (2017). DYNAMIC PREDICTION FOR MULTIPLE REPEATED MEASURES AND EVENT TIME DATA: AN APPLICATION TO PARKINSON'S DISEASE. The annals of applied statistics, 11(3), 1787-1809. https://doi.org/10.1214/17-AOAS1059
Wang, Jue, et al. "DYNAMIC PREDICTION FOR MULTIPLE REPEATED MEASURES AND EVENT TIME DATA: AN APPLICATION TO PARKINSON'S DISEASE." The annals of applied statistics vol. 11,3 (2017): 1787-1809. doi: https://doi.org/10.1214/17-AOAS1059
Wang J, Luo S, Li L. DYNAMIC PREDICTION FOR MULTIPLE REPEATED MEASURES AND EVENT TIME DATA: AN APPLICATION TO PARKINSON'S DISEASE. Ann Appl Stat. 2017 Sep;11(3):1787-1809. doi: 10.1214/17-AOAS1059. Epub 2017 Oct 05. PMID: 29081873; PMCID: PMC5656296.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1530 entries